Valeant's drug price hikes of 200-500% slammed by U.S. House Democrats
Tuesday, September 29, 2015 - 09:30
in Mathematics & Economics
Valeant Pharmaceuticals shares plunged Monday on news that the Canadian company is in the crosshairs of U.S. legislators as a result of steep price hikes on two heart drugs its sells.